Developing EXP-1801 as an imaging agent to quantify pain and analgesia
Developing EXP-1801 as an imaging agent to quantify pain and analgesia
批准号:
9909162
负责人:
BRAXTON NORWOOD
金额:
$40.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-30 至 2021-05-31
关键词:
Absence of pain sensationAcuteAcute DiseaseAcute PainAddressAdultAmericanAnalgesicsAnimal ModelAnimalsAreaBasic ScienceBehavioralBindingBiological AssayCaringChronicClinicalClinical TrialsCognitiveCommunicationDataDescriptorDetectionDevelopmentDiagnostics ResearchDiseaseEconomic BurdenEpidemicEvaluationEvolutionExhibitsGoalsHumanImageImaging technologyInfrastructureInjuryKnowledgeLidocaineLigandsLigationMalignant NeoplasmsMeasurementMeasuresMedical ResearchModelingMorphineNatureNerve TissueNeuronsOperative Surgical ProceduresOpioidPainPain MeasurementPain managementPathologicPatient Self-ReportPatientsPersonsPhasePopulationPositron-Emission TomographyRattusRecording of previous eventsReportingResearchResourcesRodentSample SizeSeveritiesSignal TransductionSodium ChannelSpinalSpinal CordSpinal nerve structureSurveysTactileTarget PopulationsTechnologyTestingTimeTissuesUnconscious StateUnited States National Institutes of HealthWestern Blottingaddictionallodyniabasechronic painclinical paincostdensitydesigndrug developmentefficacy studyexperienceexperimental studyhuman subjectimaging agentimprovedin vivoinjuredmolecular imagingnervous system disordernonhuman primatenovelnovel therapeuticsopioid abuseovertreatmentpain behaviorpain modelpain patientpain reductionpain signalpainful neuropathyphase 2 studypre-clinicalpreclinical studyresearch facilityspinal cord imagingstandard of caretargeted treatmenttherapy developmenttooltransmission processvoltage
中文摘要
摘要/文摘
英文摘要
Summary/Abstract
There are currently no tools available that can objectively measure pain. Historically, pain in humans has been
measured using subjective ratings to determine presence and severity. In animal models, pain is measured by
semi-quantitative assays that rely on the observation of pain behaviors. Though useful, the inherently
subjective nature of these measures has hampered both research and treatment efforts. Simply put, inaccurate
pain measurement leads to inaccurate pain management. Overtreatment and addiction to pain medications are
a continuing epidemic in the U.S. The estimated economic burden of chronic pain is estimated to exceed $600
billion. One advantage of an objective pain measuring technology is cost reduction. The average cost to treat a
chronic or neuropathic pain patient is $19,000 per year. These costs are exaggerated because many patients
have inadequately managed pain, which requires disproportionately more resources. A significant portion of
these costs go to patients who are not experiencing substantial pain; e.g. those who abuse opioids.
Another area where costs could be significantly reduced is in drug development. The average pain clinical trial
cost is around $71 million. The use of a pain imaging technology would allow for objective efficacy data (both
pre-clinically and in clinical trials), and reduce costs by enabling smaller sample sizes due to more
homogeneous populations; i.e. with a particular “pain signal,” and more accurate measurement of analgesic
effects.
We recently invented a novel positron emission tomography (PET) imaging agent that we developing as a tool
to address these issues in pain care and therapy development. Although the ability of PET to detect
pathological changes for (early) disease detection is widely used in cancer and neurological diseases, it has
not yet been used for pain indications. We have tested this molecule in healthy rats and non-human primates
and found a strong signal to background ratio in nerve tissue. Our ultimate goals are: 1) to change the
evaluation of (experimental) pain therapies, and 2) the standard of care in pain assessment through molecular
imaging.
The proposed study is designed to determine the feasibility of our imaging agent to objectively measure pain in
rodents. This will set the stage for a Phase II study that further develops this agent into a tool for quantifying
pain/analgesia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金